Alliance Administrative and Protocol Office Update

Trini Ajazi, MM

Clinical Research Professional Information Session

November 1, 2018

New Executive Officer

Dr Ardaman Shergill, GU & Experimental Therapeutics

Asst Professor UIC, Lung and Head & Neck

ardaman@uic.edu

ALLIANCE
FOR CLINICAL TRIALS IN ONCOLOGY

New Protocol Coordinators

Ms. Laura Hoffman, Protocol Coordinator,
Breast Committee,
hoffma12@uchicago.edu



Ms. S. Taniya Silva, Protocol Coordinator,
Neuro Oncology Committee,
stsilva@uchicago.edu

Ms. Rachel Wills, Protocol Coordinator,
CCDR, Prevention, & Health Outcomes,
rwills@uchicago.edu

ALLIANCE
FOR CLINICAL TRIALS IN ONCOLOGY

New Protocol Coordinators

Ms. Diane Feldman, Protocol Coordinator,
Leukemia Committee, *Coming Soon*



ALLIANCE
FOR CLINICAL TRIALS IN ONCOLOGY

New Alliance NCTN Chicago Personnel

Ms. Aisha Shah, Clinical Study Manager,
Registration Trials & Pharma Collaboration,
ashah@alliancenctn.org



Mr. Isiah Parker, Program Manager,
Pharma Collaboration & NCTN Budgets,
iparker@alliancenctn.org

Ms. Anne Arezina, Project Coordinator,
Pharma Relations
aarezina@alliancenctn.org

ALLIANCE
FOR CLINICAL TRIALS IN ONCOLOGY

New Alliance NCTN Chicago Personnel

Ms. Valerie Lascelles, Senior Accountant



Mr. Paul Kadota, Database Analyst

Ms. Haley Swilling, Training & Education Specialist,
hswilling@uchicago.edu

ALLIANCE
FOR CLINICAL TRIALS IN ONCOLOGY

New Alliance NCTN Chicago Personnel

Ms. Jane Ferguson, Clinical Trial Auditor

ALLIANCE
FOR CLINICAL TRIALS IN ONCOLOGY

NCI CIRB – March 1, 2019

- **All sites participating in NCTN/NCORP trials must be an NCI CIRB signatory institution, in order to enroll new patients**
- Studies activated **after** March 1, 2019
  - Any site activating/enrolling on a new NCTN/ NCORP study after March 2019, must use the CIRB as their IRB of record.

ALLIANCE
FOR CLINICAL TRIALS IN ONCOLOGY

NCI CIRB – March 1, 2019

- For any studies activated **prior** to March 1, 2019
  - Sites are not mandated to switch NCTN studies previously reviewed by a local IRB to the CIRB **but they must register each of these studies with the CIRB.** Sites that do not register their NCTN studies with the CIRB **will not be able to continue enrolling study subjects after March 1, 2019 since any new patient registrations will be blocked by CTSU.**
  - Sites that have been using a local IRB as their IRB of record for any NCTN studies they activated **prior** to March 1, 2019, do not need to transfer them. Those studies will remain with their local IRB unless the site has a compelling reason to transfer it to the CIRB, i.e., site no longer maintains a local IRB.

ALLIANCE
FOR CLINICAL TRIALS IN ONCOLOGY